Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025
Background. In 2021, new clinical guidelines for the treatment of chronic hepatitis C virus (HCV) in adults were published that did not contain interferon drug therapy regimens. Current therapy of chronic HCV is based on modern drugs of direct-acting antivirals (DAA). In this regard, the model of di...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2023-07-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/833 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|